Lion Bio teams up with MD Anderson to investigate TIL therapy in cancer

|By:, SA News Editor

Lion Biotechnologies (NASDAQ:LBIO) inks a multi-year strategic alliance with The University of Texas MD Anderson Cancer Center to evaluate the potential of tumor infiltrating lymphocyte (TIL) therapy to treat a range of cancers, including various sarcomas, ovarian and pancreatic cancer.

The clinical trials will be designed by a joint steering committee and conducted at MD Anderson. Financial terms are not disclosed.

Subscribe for full text news in your inbox